Vimarsana
Biggest News Aggregation in the World

Page 6 - Time Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Time Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Time Ventures Today - Breaking & Trending Today

Climate risk platform Cervest raises $30m in funding - Vimarsana News

Climate risk platform Cervest raises $30m in funding

The funding, which has been led by Draper Esprit, will finance the start-up’s expansion in the US and European markets.

Fintech firm Pipe secures $2bn valuation after funding round - Vimarsana News

Fintech firm Pipe secures $2bn valuation after funding round

Fintech firm Pipe secures $2bn valuation after funding round Pipe allows companies to sell their recurring revenue streams Pipe, a startup that allows companies to sell their recurring revenue streams, has secured a valuation of $2bn (£1.4bn) following a fresh funding round. The fintech firm today said it had raised a further $250m in a round led by venture capital firm Greenspring Associates.  New investors such as Morgan Stanley’s investment arm Counterpoint Global, SBI Investment and Creditease Fintech Investment Fund also contributed to the funding. Pipe, dubbed the ...

Source: cityam.com
This Israeli firm wants to hack gluten and peanut allergies. Big pharma is investing - Vimarsana News

This Israeli firm wants to hack gluten and peanut allergies. Big pharma is investing

Follow Feb. 1, 2021 Bayer, one of the largest pharmaceutical companies in the world, has led a $40 million investment in an Israeli start-up developing solutions for allergies and food sensitivities using artificial intelligence and protein engineering. The start-up, called Ukko, is focusing on two strategies. One is the growing of gluten without its allergenic components in plants such as wheat and corn, the other being the development of a medication that will “re-educate” the immune system so that it can overcome a peanut allergy. If the company succeeds in these ventures, this will ha...